By David Koenig

Boeing said Wednesday that it lost $1.2 billion in the first quarter as it and took large write-downs and lost money in both its civilian-airplane and defense businesses.

The loss was bigger than Wall Street had forecast, and the company's quarterly revenue also fell short of expectations. Boeing burned through $3.2 billion in cash.

“Messier quarter than any of us would have liked," CEO David Calhoun acknowledged on CNBC.

Shares of Boeing Co., based in Chicago, fell 10% shortly after the opening bell Wednesday.

Boeing offered some optimism for improvement, however, saying that it has submitted plans to resume deliveries of its 787 airliner and it increased production and deliveries of the 737 Max passenger jet during the quarter.

Calhoun said the company was on track to generate positive cash flow over the entire year "despite the pressures on our defense and commercial development programs.”

The quarterly report brought disappointing news for Boeing shareholders on several fronts.

The company again pushed back the expected first delivery of a new version of its long-range, twin-aisle 777 passenger jet by at least a year until 2025. The move was widely expected, as Boeing adapts to certification standards that have been tightened since regulators approved the Max, then were forced to ground the planes after two deadly crashes.

The delay in expected approval for the 777-9 caused Boeing to forecast $1.5 billion in “abnormal” production costs.

Boeing took a $660 million charge for its program to build new presidential Air Force One jets, which it blamed on higher supplier costs, final technical requirements and schedule delays. It also took $367 million in charges on a military training jet.

Boeing said it submitted plans to the Federal Aviation Administration to resume deliveries of the 787 passenger jet. Those deliveries have been halted for more than a year by production issues that Boeing previously said would add about $2 billion in costs, of which $312 million was recorded in the first quarter.

Airlines are expecting a boom summer, with travelers returning in huge numbers after two years of pandemic. But some of them, like American, have trimmed summer schedules because they haven't received the Boeing 787s that they ordered years ago.

“They have a busy summer schedule. We have already disappointed them with respect to the capacity on that summer schedule," Calhoun said. Just when Boeing will be cleared to resume deliveries of 787s is up to the FAA, but Calhoun said “We will be back in the air sooner rather than later.”

Boeing expects to boost production of the 737 Max to 31 planes a month in the current quarter, which runs through June. That plane was grounded worldwide for nearly two years after two deadly crashes.

And Boeing took $212 million in pretax charges related to Russia’s invasion of Ukraine. The company did not immediately explain the write-down.

In a memo to employees, Calhoun said Boeing is taking steps to improve long-term performance.

“We are a long-cycle business, and the success of our efforts will be measured over years and decades, not quarters,” he said.

Boeing's commercial-airplanes division lost $859 billion, hobbled by the inability to deliver 787 jets while Boeing tries to fix production flaws on the twin-aisle plane.

The defense business, long a bulwark against volatility in aircraft sales to airlines, lost $929 million as revenue fell 24%.

The company reported a loss attributable to shareholders of $1.22 billion, compared with a loss of $537 million a year earlier. The “core” loss was $2.75 a share on revenue of $13.99 billion. Analysts expected a loss of 25 cents per share on revenue of $16.02 billion, according to a FactSet survey.

Share:
More In Business
Stocks Close Lower As Investors Eye Fed Announcement, GDP, Earnings, & More
Stocks closed lower Thursday amid continued volatility. The S&P 500 was down 10% from its record high, the Dow was down 7%, and the Nasdaq was 4% away from bear market territory as it closed 16% below its record high. Investors are still processing this week's Federal Reserve announcement about a potential first rate hike in March. Chris Gaffney, President of World Markets at TIAA Bank, joins Cheddar News' Closing Bell to discuss today's close, the Fed's announcement, predictions about interest rate hikes, and more.
Crowdbotics Raises $22M Series A to Enable Anyone to Turn Ideas Into Apps
Low-code app development platform Crowdbotics raised $22 million in a Series A funding round led by Jackson Square Ventures. Crowdbotics has helped more than 14,000 customers launch apps without having to learn how to code. The company can offer a team of expert developers to help companies launch custom apps, or provide the means for companies to develop apps themselves. Crowdbotics CEO Anand Kulkarni joined Cheddar News' Closing Bell to discuss.
McDonald's Posts Q4 Earnings Miss; McPlant Burger Takes Off
McDonald's missed on both the top and bottom lines in its Q4 earnings, marking the fourth loss for the fast-food giant in the past eight quarters. It comes as higher costs from food to wages ate into the blue-chip company's profits. George Seay, CEO of investment advisor Annandale Capital, joined Wake Up with Cheddar to discuss the recent numbers and the better-than-expected success of the McPlant burger made with plant-based Beyond Meat. "They're changing with the times, and they have to," Seay noted. "You can just sell a Big Mac to everybody. There's a lot of people who don't want to eat a Big Mac anymore."
Moderna's Chief Medical Officer on Omicron Booster Trial, Annual Shots
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
Load More